Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)

NCT ID: NCT00095238

Last Updated: 2015-04-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 4128 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2002-06-30
• Study Completion Date: 2008-07-31

Brief Summary

The purpose of this clinical research study is to learn if Irbesartan is superior to placebo in reducing mortality and cardiovascular morbidity in subjects with heart failure with preserved systolic function. The safety of this treatment will also be studied.

Conditions

Congestive Heart Failure

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

1

Group Type: ACTIVE_COMPARATOR

Irbesartan

Intervention Type: DRUG

Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years

2

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years

Interventions

Irbesartan

Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years

Intervention Type: DRUG

Placebo

Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Male or female age >= 60 years with current symptoms of heart failure consistent with New York Heart Association (NYHA) class II-IV
• Left ventricular ejection fraction (LVEF) > = 45%
• Willing to provide written informed consent AND hospitalization for heart failure within the past 6 months OR various abnormalities in electrocardiogram, echocardiogram or chest x-ray indicating heart disease.

Exclusion Criteria

• Acute myocardial infarction within 3 months;
• Heart revascularization procedure within 3 months;
• Hospitalization for angina within 3 months;
• Other heart surgery
• Life-threatening or uncontrolled arrhythmia
• Subjects with an implantable cardioverter-defibrillator that has discharged in the past 3 months;
• Stroke or surgery of the arteries in the brain within 3 months;
• Serious lung disease which requires use of home oxygen.
• Significantly low blood pressure
• Significantly high blood pressure
• Other known diseases that may limit life expectancy to <3 years;
• Known or suspected bilateral kidney artery narrowing;
• Geographic or social factors making study participation and follow-up impractical.

• Minimum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sanofi

INDUSTRY

Sponsor Role: collaborator

Bristol-Myers Squibb

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Bristol-Myers Squibb

Role: STUDY_DIRECTOR

Bristol-Myers Squibb

Locations

Local Institution

Londonderry, Londonderry, United Kingdom

Local Institution

Hull, Yorkshire, United Kingdom

Local Institution

York, Yorkshire, United Kingdom

Local Institution

Dundee, , United Kingdom

Local Institution

Birmingham, Alabama, United States

Local Institution

Peoria, Arizona, United States

Local Institution

Tucson, Arizona, United States

Local Institution

Little Rock, Arkansas, United States

Local Institution

Los Angeles, California, United States

Local Institution

San Diego, California, United States

Local Institution

San Francisco, California, United States

Local Institution

Farmington, Connecticut, United States

Local Institution

Jacksonville, Florida, United States

Local Institution

Jacksonville Beach, Florida, United States

Local Institution

Lake Worth, Florida, United States

Local Institution

Tampa, Florida, United States

Local Institution

Vero Beach, Florida, United States

Local Institution

Chicago, Illinois, United States

Local Institution

Peoria, Illinois, United States

Local Institution

Jeffersonville, Indiana, United States

Local Institution

Louisville, Kentucky, United States

Local Institution

Chalmette, Louisiana, United States

Local Institution

Shreveport, Louisiana, United States

Local Institution

Auburn, Maine, United States

Local Institution

Takoma Park, Maryland, United States

Local Institution

Towson, Maryland, United States

Local Institution

Boston, Massachusetts, United States

Local Institution

Haverhill, Massachusetts, United States

Local Institution

Natick, Massachusetts, United States

Local Institution

Detroit, Michigan, United States

Local Institution

Petoskey, Michigan, United States

Local Institution

Minneapolis, Minnesota, United States

Local Institution

St Louis, Missouri, United States

Local Institution

Omaha, Nebraska, United States

Local Institution

Reno, Nevada, United States

Local Institution

Lebanon, New Hampshire, United States

Local Institution

Elmer, New Jersey, United States

Local Institution

Albuquerque, New Mexico, United States

Local Institution

Albany, New York, United States

Local Institution

East Syracuse, New York, United States

Local Institution

Flushing, New York, United States

Local Institution

Rochester, New York, United States

Local Institution

The Bronx, New York, United States

Local Institution

Troy, New York, United States

Local Institution

Chapel Hill, North Carolina, United States

Local Institution

Concord, North Carolina, United States

Local Institution

Durham, North Carolina, United States

Local Institution

Winston-Salem, North Carolina, United States

Local Institution

Canton, Ohio, United States

Local Institution

Cincinnati, Ohio, United States

Local Institution

Columbus, Ohio, United States

Local Institution

Lorain, Ohio, United States

Local Institution

Sandusky, Ohio, United States

Local Institution

Portland, Oregon, United States

Local Institution

Flourtown, Pennsylvania, United States

Local Institution

Lancaster, Pennsylvania, United States

Local Institution

Charleston, South Carolina, United States

Local Institution

Germantown, Tennessee, United States

Local Institution

Austin, Texas, United States

Local Institution

Lynchberg, Virginia, United States

Local Institution

Richmond, Virginia, United States

Local Institution

South Boston, Virginia, United States

Local Institution

Spokane, Washington, United States

Local Institution

Madison, Wisconsin, United States

Local Institution

Buenos Aires, Buenos Aires, Argentina

Local Institution

San Martín, Buenos Aires, Argentina

Local Institution

Corrientes, Corrientes Province, Argentina

Local Institution

Córdoba, Córdoba Province, Argentina

Local Institution

Mendoza, Mendoza Province, Argentina

Local Institution

Rosario, Santa Fe Province, Argentina

Local Institution

Coffs Harbour, New South Wales, Australia

Local Institution

Concord, New South Wales, Australia

Local Institution

Garran, New South Wales, Australia

Local Institution

Kogarah, New South Wales, Australia

Local Institution

Randwick, New South Wales, Australia

Local Institution

Auchenflower, Queensland, Australia

Local Institution

Brisbane, Queensland, Australia

Local Institution

Woolloongabba, Queensland, Australia

Local Institution

Launceston, Tasmania, Australia

Local Institution

Geelong, Victoria, Australia

Local Institution

Prahran, Victoria, Australia

Local Institution

Aalst, , Belgium

Local Institution

Aye, , Belgium

Local Institution

Borgerhout, , Belgium

Local Institution

Genk-waterschei, , Belgium

Local Institution

Ghent, , Belgium

Local Institution

Hasselt, , Belgium

Local Institution

Huy, , Belgium

Local Institution

Leuven, , Belgium

Local Institution

Verviers, , Belgium

Local Institution

Salvador, Estado de Bahia, Brazil

Local Institution

Goiania-go, Goiás, Brazil

Local Institution

Belo Horizonte, Minas Gerais, Brazil

Local Institution

Rio de Janeiro, Rio de Janeiro, Brazil

Local Institution

Campinas, São Paulo, Brazil

Local Institution

Sao Paulo, Sp, São Paulo, Brazil

Local Institution

Calgary, Alberta, Canada

Local Institution

Victoria, British Columbia, Canada

Local Institution

Ajax, Ontario, Canada

Local Institution

Hamilton, Ontario, Canada

Local Institution

Rexdale, Ontario, Canada

Local Institution

Scarborough Village, Ontario, Canada

Local Institution

Toronto, Ontario, Canada

Local Institution

Weston, Ontario, Canada

Local Institution

Longueuil, Quebec, Canada

Local Institution

Montreal, Quebec, Canada

Local Institution

Saint-Lambert, Quebec, Canada

Local Institution

Ste-Foy, Quebec, Canada

Local Institution

Prague, , Czechia

Local Institution

Ústí nad Labem, , Czechia

Local Institution

Copenhagen, , Denmark

Local Institution

Copenhagen Nv, , Denmark

Local Institution

Abbeville, , France

Local Institution

Cholet, , France

Local Institution

Dax, , France

Local Institution

Gap, , France

Local Institution

Langres, , France

Local Institution

Lille, , France

Local Institution

Montbéliard, , France

Local Institution

Paris, , France

Local Institution

Poissy, , France

Local Institution

Pontoise, , France

Local Institution

Provins, , France

Local Institution

Roubaix, , France

Local Institution

Rouen, , France

Local Institution

St-Malo, , France

Local Institution

Tours, , France

Local Institution

Vandœuvre-lès-Nancy, , France

Local Institution

Vichy, , France

Local Institution

Bad Homburg, , Germany

Local Institution

Berlin, , Germany

Local Institution

Göttingen, , Germany

Local Institution

Gunzenhausen, , Germany

Local Institution

Halle, , Germany

Local Institution

Homburg / Saar, , Germany

Local Institution

Jena, , Germany

Local Institution

Langen, , Germany

Local Institution

Leipzig, , Germany

Local Institution

Mainz, , Germany

Local Institution

Marburg, , Germany

Local Institution

München, , Germany

Local Institution

Regensburg, , Germany

Local Institution

Stuttgart, , Germany

Local Institution

Witten, , Germany

Local Institution

Würzburg, , Germany

Local Institution

Athens, , Greece

Local Institution

Pátrai, , Greece

Local Institution

Budapest, , Hungary

Local Institution

Debrecen, , Hungary

Local Institution

Siófok, , Hungary

Local Institution

Szeged, , Hungary

Local Institution

County Dublin, Dublin, Ireland

Local Institution

Dublin, Dublin, Ireland

Local Institution

Ascoli Piceno, , Italy

Local Institution

Bologna, , Italy

Local Institution

Brescia, , Italy

Local Institution

Cosenza, , Italy

Local Institution

Pavia, , Italy

Local Institution

Perugia, , Italy

Local Institution

Piacenza, , Italy

Local Institution

Roma, , Italy

Local Institution

Siena, , Italy

Local Institution

Trieste, , Italy

Local Institution

Udine, , Italy

Local Institution

Aguascalientes, Aguascalientes, Mexico

Local Institution

Guadalajara, Jalisco, Mexico

Local Institution

Mexico City, Mexico City, Mexico

Local Institution

San Pedro Garza García, Nuevo León, Mexico

Local Institution

Alkmaar, , Netherlands

Local Institution

Almere Stad, , Netherlands

Local Institution

Amersfoort, , Netherlands

Local Institution

Apeldoorn, , Netherlands

Local Institution

Assen, , Netherlands

Local Institution

Breda, , Netherlands

Local Institution

Delft, , Netherlands

Local Institution

Emmen, , Netherlands

Local Institution

Gorinchem, , Netherlands

Local Institution

Groningen, , Netherlands

Local Institution

Heemstede, , Netherlands

Local Institution

Helmond, , Netherlands

Local Institution

Hengelo Ov, , Netherlands

Local Institution

Nijmegen, , Netherlands

Local Institution

Rotterdam, , Netherlands

Local Institution

Sittard, , Netherlands

Local Institution

Sneek, , Netherlands

Local Institution

Veldhoven, , Netherlands

Local Institution

Vlaardingen, , Netherlands

Local Institution

Zaandam, , Netherlands

Local Institution

Baerum Postterminal, , Norway

Local Institution

Stavanger, , Norway

Local Institution

Tønsberg, , Norway

Local Institution

Bydgoszcz, , Poland

Local Institution

Katowice, , Poland

Local Institution

Piotrkow Tryb., , Poland

Local Institution

Stalowa Wola, , Poland

Local Institution

Warsaw, , Poland

Local Institution

Wroclaw, , Poland

Local Institution

Lisbon, , Portugal

Local Institution

Matosinhos Municipality, , Portugal

Local Institution

Moscow, , Russia

Local Institution

Saint Petersburg, , Russia

Local Institution

Saratov, , Russia

Local Institution

Johannesburg, Gauteng, South Africa

Local Institution

Morningside, Gauteng, South Africa

Local Institution

Parktown West, Gauteng, South Africa

Local Institution

Berea, KwaZulu-Natal, South Africa

Local Institution

KwaKhangela, KwaZulu-Natal, South Africa

Local Institution

A Coruña, , Spain

Local Institution

Barcelona, , Spain

Local Institution

Córdoba, , Spain

Local Institution

Madrid, , Spain

Local Institution

Málaga, , Spain

Local Institution

Murcia, , Spain

Local Institution

Palma de Mallorca, , Spain

Local Institution

Seville, , Spain

Local Institution

Valencia, , Spain

Local Institution

Zaragoza, , Spain

Local Institution

Falun, , Sweden

Local Institution

Gothenburg, , Sweden

Local Institution

Linköping, , Sweden

Local Institution

Malmo, , Sweden

Local Institution

Skellefteå, , Sweden

Local Institution

Stockholm, , Sweden

Local Institution

Sundsvall, , Sweden

Local Institution

Bellinzona, , Switzerland

Local Institution

Liestal, , Switzerland

Local Institution

Zurich, , Switzerland

Local Institution

Glasgow, Dumbartonshire, United Kingdom

Local Institution

Romford, Essex, United Kingdom

Countries

United States; Argentina; Australia; Belgium; Brazil; Canada; Czechia; Denmark; France; Germany; Greece; Hungary; Ireland; Italy; Mexico; Netherlands; Norway; Poland; Portugal; Russia; South Africa; Spain; Sweden; Switzerland; United Kingdom

References

Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008 Dec 4;359(23):2456-67. doi: 10.1056/NEJMoa0805450. Epub 2008 Nov 11.

Reference Type: RESULT

PMID: 19001508 (View on PubMed)

Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, Lopez-Sendon J, Teerlink JR, White M, McMurray JJ, Komajda M, McKelvie R, Ptaszynska A, Hetzel SJ, Massie BM, Carson PE; I-Preserve Investigators. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation. 2010 Mar 30;121(12):1393-405. doi: 10.1161/CIRCULATIONAHA.109.909614. Epub 2010 Mar 15.

Reference Type: RESULT

PMID: 20231531 (View on PubMed)

McMurray JJ, Carson PE, Komajda M, McKelvie R, Zile MR, Ptaszynska A, Staiger C, Donovan JM, Massie BM. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail. 2008 Feb;10(2):149-56. doi: 10.1016/j.ejheart.2007.12.010.

Reference Type: RESULT

PMID: 18279770 (View on PubMed)

Carson P, Massie BM, McKelvie R, McMurray J, Komajda M, Zile M, Ptaszynska A, Frangin G; I-PRESERVE Investigators. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail. 2005 Oct;11(8):576-85. doi: 10.1016/j.cardfail.2005.06.432.

Reference Type: RESULT

PMID: 16230259 (View on PubMed)

McKelvie RS, Komajda M, McMurray J, Zile M, Ptaszynska A, Donovan M, Carson P, Massie BM; I-Preserve Investigators. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. J Card Fail. 2010 Feb;16(2):128-34. doi: 10.1016/j.cardfail.2009.09.007. Epub 2009 Nov 4.

Reference Type: RESULT

PMID: 20142024 (View on PubMed)

Lassen MCH, Ostrominski JW, Claggett BL, Neuen BL, Beldhuis IE, Butt JH, Biering-Sorensen T, Desai AS, Lewis EF, Jhund PS, Mc Causland F, Anand IS, Pfeffer MA, Pitt B, Zannad F, Zile MR, McMurray JJV, Solomon SD, Vaduganathan M. Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction: A Participant-Level Pooled Analysis of 4 Contemporary Trials. JACC Heart Fail. 2025 Aug;13(8):102498. doi: 10.1016/j.jchf.2025.03.042. Epub 2025 Jun 9.

Reference Type: DERIVED

PMID: 40494011 (View on PubMed)

Kondo T, Campbell R, Jhund PS, Anand IS, Carson PE, Lam CSP, Shah SJ, Vaduganathan M, Zannad F, Zile MR, Solomon SD, McMurray JJV. Low Natriuretic Peptide Levels and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JACC Heart Fail. 2024 Aug;12(8):1442-1455. doi: 10.1016/j.jchf.2024.04.027. Epub 2024 Jun 19.

Reference Type: DERIVED

PMID: 38904646 (View on PubMed)

Kondo T, Dewan P, Anand IS, Desai AS, Packer M, Zile MR, Pfeffer MA, Solomon SD, Abraham WT, Shah SJ, Lam CSP, Jhund PS, McMurray JJV. Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification? Circulation. 2023 Aug 29;148(9):732-749. doi: 10.1161/CIRCULATIONAHA.122.063642. Epub 2023 Jun 27.

Reference Type: DERIVED

PMID: 37366061 (View on PubMed)

Kondo T, Jering KS, Jhund PS, Anand IS, Desai AS, Lam CSP, Maggioni AP, Martinez FA, Packer M, Petrie MC, Pfeffer MA, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Solomon SD, McMurray JJV. Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial Fibrillation. Circ Heart Fail. 2023 Jul;16(7):e010377. doi: 10.1161/CIRCHEARTFAILURE.122.010377. Epub 2023 Jun 23.

Reference Type: DERIVED

PMID: 37350280 (View on PubMed)

Curtain JP, Adamson C, Kondo T, Butt JH, Desai AS, Zannad F, Rouleau JL, Rohde LE, Kober L, Anand IS, van Veldhuisen DJ, Zile MR, Lefkowitz MP, Solomon SD, Packer M, Petrie MC, Jhund PS, McMurray JJV. Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction. Eur Heart J. 2023 Feb 21;44(8):668-677. doi: 10.1093/eurheartj/ehac801.

Reference Type: DERIVED

PMID: 36632831 (View on PubMed)

Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, Granger CB, Kober L, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Swedberg K, Zile MR, McMurray JJV. Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. Clin Res Cardiol. 2021 Aug;110(8):1234-1248. doi: 10.1007/s00392-020-01786-8. Epub 2020 Dec 10.

Reference Type: DERIVED

PMID: 33301080 (View on PubMed)

Tromp J, Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Kober L, Swedberg K, Zile MR, Pitt B, Lam CSP, McMurray JJV. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2019 Aug 6;74(5):601-612. doi: 10.1016/j.jacc.2019.05.052.

Reference Type: DERIVED

PMID: 31370950 (View on PubMed)

Kristensen SL, Mogensen UM, Jhund PS, Rorth R, Anand IS, Carson PE, Desai AS, Pitt B, Pfeffer MA, Solomon SD, Zile MR, Kober L, McMurray JJV. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. Circ Heart Fail. 2019 Mar;12(3):e005766. doi: 10.1161/CIRCHEARTFAILURE.118.005766.

Reference Type: DERIVED

PMID: 30871349 (View on PubMed)

Kristensen SL, Mogensen UM, Jhund PS, Petrie MC, Preiss D, Win S, Kober L, McKelvie RS, Zile MR, Anand IS, Komajda M, Gottdiener JS, Carson PE, McMurray JJ. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation. 2017 Feb 21;135(8):724-735. doi: 10.1161/CIRCULATIONAHA.116.024593. Epub 2017 Jan 4.

Reference Type: DERIVED

PMID: 28052977 (View on PubMed)

Gandhi PU, Chow SL, Rector TS, Krum H, Gaggin HK, McMurray JJ, Zile MR, Komajda M, McKelvie RS, Carson PE, Januzzi JL Jr, Anand IS. Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. J Card Fail. 2017 Jan;23(1):20-28. doi: 10.1016/j.cardfail.2016.06.006. Epub 2016 Jun 16.

Reference Type: DERIVED

PMID: 27317843 (View on PubMed)

Badar AA, Perez-Moreno AC, Hawkins NM, Jhund PS, Brunton AP, Anand IS, McKelvie RS, Komajda M, Zile MR, Carson PE, Gardner RS, Petrie MC, McMurray JJ. Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial. Circ Heart Fail. 2015 Jul;8(4):717-24. doi: 10.1161/CIRCHEARTFAILURE.114.002024. Epub 2015 Jun 11.

Reference Type: DERIVED

PMID: 26067854 (View on PubMed)

Oluleye OW, Rector TS, Win S, McMurray JJ, Zile MR, Komajda M, McKelvie RS, Massie B, Carson PE, Anand IS. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2014 Nov;7(6):960-6. doi: 10.1161/CIRCHEARTFAILURE.114.001523. Epub 2014 Sep 15.

Reference Type: DERIVED

PMID: 25225241 (View on PubMed)

Bohm M, Perez AC, Jhund PS, Reil JC, Komajda M, Zile MR, McKelvie RS, Anand IS, Massie BM, Carson PE, McMurray JJ; I-Preserve Committees and Investigators. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). Eur J Heart Fail. 2014 Jul;16(7):778-87. doi: 10.1002/ejhf.85. Epub 2014 May 23.

Reference Type: DERIVED

PMID: 24864045 (View on PubMed)

Lam CS, Carson PE, Anand IS, Rector TS, Kuskowski M, Komajda M, McKelvie RS, McMurray JJ, Zile MR, Massie BM, Kitzman DW. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2012 Sep 1;5(5):571-8. doi: 10.1161/CIRCHEARTFAILURE.112.970061. Epub 2012 Aug 10.

Reference Type: DERIVED

PMID: 22887722 (View on PubMed)

Rector TS, Carson PE, Anand IS, McMurray JJ, Zile MR, McKelvie RS, Komajda M, Kuskowski M, Massie BM; I-PRESERVE Trial Investigators. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circ Heart Fail. 2012 Mar 1;5(2):217-25. doi: 10.1161/CIRCHEARTFAILURE.111.964221. Epub 2012 Jan 20.

Reference Type: DERIVED

PMID: 22267751 (View on PubMed)

Zile MR, Gottdiener JS, Hetzel SJ, McMurray JJ, Komajda M, McKelvie R, Baicu CF, Massie BM, Carson PE; I-PRESERVE Investigators. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation. 2011 Dec 6;124(23):2491-501. doi: 10.1161/CIRCULATIONAHA.110.011031. Epub 2011 Nov 7.

Reference Type: DERIVED

PMID: 22064591 (View on PubMed)

Krum H, Elsik M, Schneider HG, Ptaszynska A, Black M, Carson PE, Komajda M, Massie BM, McKelvie RS, McMurray JJ, Zile MR, Anand IS. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circ Heart Fail. 2011 Sep;4(5):561-8. doi: 10.1161/CIRCHEARTFAILURE.110.960716. Epub 2011 Jul 12.

Reference Type: DERIVED

PMID: 21750125 (View on PubMed)

Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H, McMurray JJ, Zile MR, Komajda M, Massie BM, Carson PE. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail. 2011 Sep;4(5):569-77. doi: 10.1161/CIRCHEARTFAILURE.111.962654. Epub 2011 Jun 29.

Reference Type: DERIVED

PMID: 21715583 (View on PubMed)

Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM, Carson PE. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2011 May;4(3):324-31. doi: 10.1161/CIRCHEARTFAILURE.110.959890. Epub 2011 Feb 24.

Reference Type: DERIVED

PMID: 21350053 (View on PubMed)

Komajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, Ptaszynska A, Zile MR, Demets D, Massie BM. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail. 2011 Jan;4(1):27-35. doi: 10.1161/CIRCHEARTFAILURE.109.932996. Epub 2010 Nov 10.

Reference Type: DERIVED

PMID: 21068341 (View on PubMed)

Other Identifiers

CV131-148

Identifier Type: -

Identifier Source: org_study_id